The Effect of Teriparatide [Human Parathyroid Hormone (1–34)] Therapy on Bone Density in Men With Osteoporosis

By E. Orwoll, W. Scheele, Susmita Paul, S. Adami, U. Syversen, A. Díez-Pérez, J. Kaufman, A. Clancy, G. Gaich. Journal of Bone and Mineral Research, 2003

767 citations recorded by the source corpus.

Subfields: Nephrology, Oncology, Orthopedics and Sports Medicine

View Paper: https://www.semanticscholar.org/paper/c92dedb6f7a75c15031a8121db415efcdfa6c9a8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Eugene V. McCloskey
2. Chris Cooper
3. M. McClung
4. J. Kanis

In Orthopedics and Sports Medicine

1. Chris Cooper
2. Eugene V. McCloskey
3. J. Kanis
4. Nicholas C. Harvey
5. M. McClung
6. H. Johansson
7. J. Reginster
8. R. Rizzoli

Citations in the corpus

• The decline of androgen levels in elderly men and its clinical and therapeutic implications. (2005, background): “Moreover, for oral alendronate (465) and for daily sc injections of recombinant (1–34)PTH (466), two drugs presently available for treatment of men with low BMD, it has been documented that, combined with calcium and vitamin D supplements, these drugs have beneficial effects on BMD independent of ag”
• UK clinical guideline for the prevention and treatment of osteoporosis (2017, background): “bridging studies [73, 80, 85, 88, 98], although reduction in vertebral fractures has also shown in men with oste-”
• Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. (2005, background): “Similar transient rises in serum calcium have been reported during other controlled trials with teriparatide (51, 86).”